R Rosell
Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC-a systematic review and meta-analysis.
Dafni U, Soo R, Peters S, Tsourti Z, Zygoura P, Vervita K, Han J, de Castro J, Coate L, Früh M, Hashemi S, Nadal E, Carcereny E, Sala M, Bernabé R, Provencio Pulla M, Cuffe S, Roschitzki-Voser H, Ruepp B, Rosell R, Stahel R. Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC-a systematic review and meta-analysis. ESMO Open 2022; 7:100507.
10.06.2022Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC-a systematic review and meta-analysis.
10.06.2022ESMO Open 2022; 7:100507
Dafni U, Soo R A, Peters S, Tsourti Zoi, Zygoura P, Vervita K, Han J-Y, de Castro J, Coate L, Früh M, Hashemi S M S, Nadal E, Carcereny E, Sala M A, Bernabé R, Provencio Pulla M, Cuffe S, Roschitzki-Voser H, Ruepp B, Rosell R, Stahel R A
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial.
Soo R, Han J, Dafni U, Cho B, Yeo C, Nadal E, Carcereny E, de Castro J, Sala M, Bernabé R, Coate L, Provencio Pulla M, Garcia Campelo R, Cuffe S, Hashemi S, Früh M, Massuti B, Garcia-Sanchez J, Dómine M, Majem M, Sanchez-Torres J, Britschgi C, Pless M, Dimopoulou G, Roschitzki-Voser H, Ruepp B, Rosell R, Stahel R, Peters S, ETOP 10-16 BOOSTER Collaborators. A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial. Ann Oncol 2021; 33:181-192.
26.11.2021A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial.
26.11.2021Ann Oncol 2021; 33:181-192
Soo R A, Han J-Y, Dafni U, Cho B C, Yeo C M, Nadal E, Carcereny E, de Castro J, Sala M A, Bernabé R, Coate L, Provencio Pulla M, Garcia Campelo R, Cuffe S, Hashemi S M S, Früh M, Massuti B, Garcia-Sanchez J, Dómine M, Majem M, Sanchez-Torres J-M, Britschgi C, Pless M, Dimopoulou G, Roschitzki-Voser H, Ruepp B, Rosell R, Stahel R A, Peters S, ETOP 10-16 BOOSTER Collaborators
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
Mazières J, Rothschild S, Bironzo P, Martinez A, Curioni-Fontecedro A, Rosell R, Lattuca-Truc M, Wiesweg M, Besse B, Solomon B, Barlesi F, Schouten R, Wakelee H, Camidge D, Zalcman G, Novello S, Ou S, Milia J, Zhu V, Sabari J, Drilon A, Lusque A, Mhanna L, Cortot A, Mezquita L, Thai A, Mascaux C, Couraud S, Veillon R, Van Den Heuvel M, Neal J, Peled N, Früh M, Ng T, Gounant V, Popat S, Diebold J, Gautschi O. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol 2019
24.05.2019Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
24.05.2019Ann Oncol 2019
Mazières J, Rothschild S I, Bironzo P, Martinez A, Curioni-Fontecedro A, Rosell R, Lattuca-Truc M, Wiesweg M, Besse B, Solomon B, Barlesi F, Schouten R D, Wakelee H, Camidge D R, Zalcman G, Novello S, Ou S I, Milia J, Zhu V W, Sabari J, Drilon A, Lusque A, Mhanna L, Cortot A B, Mezquita L, Thai A A, Mascaux C, Couraud S, Veillon R, Van Den Heuvel M, Neal J, Peled N, Früh Martin, Ng T L, Gounant V, Popat S, Diebold J, Gautschi O
Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort
Mazières J, Milia J, Moro-Sibilot D, Cortot A, Cappuzzo F, Westeel V, Fournel P, Wislez M, Rosell R, Pless M, Früh M, Dansin E, Peters S, Beau-Faller M, Monnet I, Besse B, Filleron T, Barlesi F, Gautschi O. Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort. Ann Oncol 2015; 27:281-6.
23.11.2015Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort
23.11.2015Ann Oncol 2015; 27:281-6
Mazières J, Milia J, Moro-Sibilot D, Cortot A, Cappuzzo F, Westeel V, Fournel P, Wislez M, Rosell R, Pless M, Früh Martin, Dansin E, Peters S, Beau-Faller M, Monnet I, Besse B, Filleron T, Barlesi F, Gautschi O
Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010
Felip E, Gridelli C, Baas P, Rosell R, Stahel R, Panel members. Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010. Ann Oncol 2011; 22:1507-1519.
01.07.2011Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010
01.07.2011Ann Oncol 2011; 22:1507-1519
Felip E, Gridelli C, Baas P, Rosell R, Stahel R, Panel members